Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

In the early hours of September 14 2021, three men parked in a quiet car park in the southern English market town of Abingdon-on-Thames. The men ...

Gov. Ned Lamont eyed Medicaid reimbursement rates, a hospital tax restructuring and pharmaceutical costs in his biennial ...

Cardiovascular diseases (CVDs) are the key factors leading to death and disability worldwide. This severe challenge has prompted the scientific research and ...

The American Cancer Society is calling on the Trump administration to restore access to comprehensive scientific data.

President Donald Trump signed executive orders imposing tariffs on almost all imports from Canada, Mexico and China. Tariffs ...

Research and development (R&D) expenses for the fourth quarter and full year 2024 were $1.3 million and $10.5 million, respectively, compared to $9.7 million and $40.0 million for the same periods in ...

In November, virologist Beata Halassy announced to the world that she had cured her own breast cancer using a treatment ...

Dr. Carrie Jose, in her latest Health and Wellness column, provides six natural ways to relieve arthritis pain - without meds ...

The art of saying no in clinical trials goes beyond simply delivering news; it involves maintaining relationships and ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...